BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 19562340)

  • 21. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
    Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
    Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
    André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
    J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
    Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
    Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens.
    Dudley ME; Roopenian DC
    J Exp Med; 1996 Aug; 184(2):441-7. PubMed ID: 8760797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma.
    Noguchi Y; Richards EC; Chen YT; Old LJ
    Proc Natl Acad Sci U S A; 1995 Mar; 92(6):2219-23. PubMed ID: 7892250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells.
    Muraoka D; Kato T; Wang L; Maeda Y; Noguchi T; Harada N; Takeda K; Yagita H; Guillaume P; Luescher I; Old LJ; Shiku H; Nishikawa H
    J Immunol; 2010 Sep; 185(6):3768-76. PubMed ID: 20733202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses.
    Breckpot K; Heirman C; De Greef C; van der Bruggen P; Thielemans K
    J Immunol; 2004 Feb; 172(4):2232-7. PubMed ID: 14764691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy.
    Ikuta Y; Katayama N; Wang L; Okugawa T; Takahashi Y; Schmitt M; Gu X; Watanabe M; Akiyoshi K; Nakamura H; Kuribayashi K; Sunamoto J; Shiku H
    Blood; 2002 May; 99(10):3717-24. PubMed ID: 11986228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Properties of a M(r) 110,000 tumor rejection antigen of the chemically induced BALB/c Meth A sarcoma.
    De Leo AB; Becker M; Lu L; Law LW
    Cancer Res; 1993 Apr; 53(7):1602-7. PubMed ID: 7680955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Identification of a novel HLA-A2-restrictive CTL epitope of an ovary cancer-associated antigen OVA66].
    Jin S; Wang Y; Wang SJ; Zhang HZ; Li MX; Chen Y; Ge HL
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Mar; 21(2):233-6, 242. PubMed ID: 15766414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy.
    Rosato A; Zoso A; Milan G; Macino B; Dalla Santa S; Tosello V; Di Carlo E; Musiani P; Whalen RG; Zanovello P
    J Immunol; 2003 Nov; 171(10):5172-9. PubMed ID: 14607917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infiltration of H-2d-specific cytotoxic macrophage with unique morphology into rejection site of allografted meth A (H-2d) tumor cells in C57BL/6 (H-2b) mice.
    Nomi H; Tashiro-Yamaji J; Miura-Takeda S; Shimizu T; Azuma H; Ueda H; Katsuoka Y; Kubota T; Yoshida R
    Microbiol Immunol; 2007; 51(3):297-306. PubMed ID: 17380049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
    Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
    J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The soluble antigens of BALB/c sarcoma Meth-A: a relationship between a serologically defined tumor-specific surface antigen (TSSA) and the tumor-associated transplantation antigen (TATA).
    DuBois GC; Appella E; Law LW; DeLeo AB; Old LJ
    Transplant Proc; 1981 Dec; 13(4):1765-73. PubMed ID: 6173944
    [No Abstract]   [Full Text] [Related]  

  • 36. Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens.
    Wang RF
    Immunol Rev; 2002 Oct; 188():65-80. PubMed ID: 12445282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts.
    Gabrilovich DI; Ciernik IF; Carbone DP
    Cell Immunol; 1996 May; 170(1):101-10. PubMed ID: 8665590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. H-40, an antigen controlled by an Igh-linked gene and recognized by cytotoxic T lymphocytes. II. Recognition of H-40 as a tumor antigen in leukemic animals.
    Henderson LA; Ciavarra R; Riblet R; Forman J
    J Immunol; 1984 Nov; 133(5):2778-85. PubMed ID: 6434638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers.
    Peoples GE; Anderson BW; Lee TV; Murray JL; Kudelka AP; Wharton JT; Ioannides CG
    Clin Cancer Res; 1999 Dec; 5(12):4214-23. PubMed ID: 10632363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity.
    Casares N; Lasarte JJ; de Cerio AL; Sarobe P; Ruiz M; Melero I; Prieto J; BorrĂ¡s-Cuesta F
    Eur J Immunol; 2001 Jun; 31(6):1780-9. PubMed ID: 11385623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.